{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:44:16Z","timestamp":1793933056869,"version":"4.8.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000725","name":"The","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000545","name":"British Association of Dermatologists","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007472","name":"UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007472","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000764","name":"King\u2019s College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000764","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Lilly","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The main conventional systemic treatments for atopic dermatitis (AD) are methotrexate (MTX) and ciclosporin (CyA). Dupilumab was the first novel systemic agent to enter routine clinical practice. There are no head-to-head randomized controlled trials or real-world studies comparing these agents directly. Network meta-analyses provide indirect comparative efficacy and safety data and have shown strong evidence for dupilumab and CyA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare the real-world clinical effectiveness and safety of CyA, dupilumab and MTX in AD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We compared the effectiveness and safety of these systemic agents in a prospective observational cohort study of adult and paediatric patients recruited into the UK\u2013Irish Atopic eczema Systemic TherApy Register (A-STAR). Treatment effectiveness measures included Eczema Area and Severity Index (EASI), Patient-Oriented Eczema Measure (POEM), Peak Pruritus Numerical Rating Scale (PP-NRS), Dermatology Life Quality Index (DLQI) and children\u2019s DLQI (cDLQI). The minimum duration of treatment was 28\u2005days and follow-up was 12\u2005months. Adjusted Cox-regression analysis was used to compare the hazard ratios of achieving EASI-50, EASI-75 and EASI-90 over time, and linear mixed-effects models were used to estimate changes in efficacy scores. Treatment safety was assessed by examining adverse events (AEs) at follow-up visits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 488 patients (311 adults and 177 children\/adolescents) on dupilumab (n = 282), MTX (n = 149) or CyA (n = 57). CyA and MTX were primarily used as the first-line treatment, while dupilumab was mainly a second-line systemic treatment as per UK National Institute of Clinical and Care Excellence (NICE) recommendations. EASI-50, EASI-75 and EASI-90 were achieved more rapidly in the dupilumab and CyA groups compared with MTX. After adjustment for previous severity, the reduction in EASI, POEM, PP-NRS and DLQI was greater for patients treated with dupilumab compared with MTX. In patients with severe disease the reduction in EASI, POEM and PP-NRS was even greater with CyA. The incidence rates of AEs were similar across groups (734, 654 and 594 per 10 000 person-month on CyA, dupilumab and MTX, respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This real-world comparison of CyA, dupilumab and MTX in AD suggests that dupilumab is consistently more effective than MTX and that CyA is most effective in very severe disease within 1\u2005year of follow-up.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljae287","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T02:34:21Z","timestamp":1721788461000},"page":"988-999","source":"Crossref","is-referenced-by-count":19,"title":["A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK\u2013Irish A-STAR register"],"prefix":"10.1093","volume":"191","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0241-5408","authenticated-orcid":false,"given":"Helen","family":"Alexander","sequence":"first","affiliation":[{"name":"Unit for Paediatric & Population-Based Dermatology Research, St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust and King\u2019s College London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayka","family":"Malek","sequence":"additional","affiliation":[{"name":"Unit for Paediatric & Population-Based Dermatology Research, St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust and King\u2019s College London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Prieto-Merino","sequence":"additional","affiliation":[{"name":"Unit for Paediatric & Population-Based Dermatology Research, St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust and King\u2019s College London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizaveta","family":"Gribaleva","sequence":"additional","affiliation":[{"name":"Unit for Paediatric & Population-Based Dermatology Research, St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust and King\u2019s College London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Baden","sequence":"additional","affiliation":[{"name":"Unit for Paediatric & Population-Based Dermatology Research, St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust and King\u2019s College London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Beattie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shona","family":"Cameron","sequence":"additional","affiliation":[{"name":"Unit for Paediatric & Population-Based Dermatology Research, St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust and King\u2019s College London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bola","family":"Coker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Cork","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Hearn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5257-1142","authenticated-orcid":false,"given":"John R","family":"Ingram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D","family":"Irvine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7494-0765","authenticated-orcid":false,"given":"Graham A","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Newell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Ogg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Patel","sequence":"additional","affiliation":[{"name":"Unit for Paediatric & Population-Based Dermatology Research, St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust and King\u2019s College London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2918-6481","authenticated-orcid":false,"given":"Richard\u00a0B","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Woolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1831-074X","authenticated-orcid":false,"given":"Zenas Z N","family":"Yiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1466-2016","authenticated-orcid":false,"given":"Michael R","family":"Ardern-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4884-6286","authenticated-orcid":false,"given":"Carsten","family":"Flohr","sequence":"additional","affiliation":[{"name":"Unit for Paediatric & Population-Based Dermatology Research, St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust and King\u2019s College London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"key":"2024111803540975400_ljae287-B1","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.det.2017.02.002","article-title":"Public health burden and epidemiology of atopic dermatitis","volume":"35","author":"Silverberg","year":"2017","journal-title":"Dermatol Clin"},{"key":"2024111803540975400_ljae287-B2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jid.2016.07.012","article-title":"The burden of atopic dermatitis: summary of a report for the National Eczema Association","volume":"137","author":"Drucker","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"key":"2024111803540975400_ljae287-B3","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1111\/bjd.15235","article-title":"Treatment of moderate-to-\u00adsevere atopic eczema in adults within the U.K.: results of a national survey of dermatologists","volume":"176","author":"Taylor","year":"2017","journal-title":"Br J Dermatol"},{"key":"2024111803540975400_ljae287-B4","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/all.14631","article-title":"Systemic treatments in the management of atopic dermatitis: a systematic review and meta-analysis","volume":"76","author":"Siegels","year":"2021","journal-title":"Allergy"},{"key":"2024111803540975400_ljae287-B5","doi-asserted-by":"crossref","first-page":"adv00573","DOI":"10.2340\/00015555-3886","article-title":"Rapid and sustained effect of dupilumab on work productivity in patients with difficult-to-treat atopic dermatitis: results from the Dutch BioDay Registry","volume":"101","author":"Ari\u00ebns","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"2024111803540975400_ljae287-B6","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/all.14080","article-title":"Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: first clinical and biomarker results from the BioDay registry","volume":"75","author":"Ari\u00ebns","year":"2020","journal-title":"Allergy"},{"key":"2024111803540975400_ljae287-B7","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1080\/09546634.2021.1937485","article-title":"Eczema control and treatment satisfaction in atopic dermatitis patients treated with dupilumab \u2013 a cross-sectional study from the BioDay registry","volume":"33","author":"Oosterhaven","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"2024111803540975400_ljae287-B8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaad.2019.02.053","article-title":"Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort","volume":"81","author":"Faiz","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2024111803540975400_ljae287-B9","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4168\/aair.2022.14.1.117","article-title":"One-year effectiveness and safety of dupilumab treatment for moderate-to-severe atopic dermatitis in Korean patients: a real-world retrospective analysis","volume":"14","author":"Lee","year":"2022","journal-title":"Allergy Asthma Immunol Res"},{"key":"2024111803540975400_ljae287-B10","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jaad.2020.05.128","article-title":"Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry","volume":"83","author":"Bosma","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2024111803540975400_ljae287-B11","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00431-012-1893-3","article-title":"Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt","volume":"172","author":"El-Khalawany","year":"2013","journal-title":"Eur J Pediatr"},{"key":"2024111803540975400_ljae287-B12","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jaip.2017.07.007","article-title":"Methotrexate versus cyclosporine in adults with moderate-to-severe atopic dermatitis: a phase III randomized noninferiority trial","volume":"6","author":"Goujon","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024111803540975400_ljae287-B13","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/bjd.16240","article-title":"Methotrexate and azathioprine for severe atopic dermatitis: a 5-year follow-up study of a randomized controlled trial","volume":"178","author":"Gerbens","year":"2018","journal-title":"Br J Dermatol"},{"key":"2024111803540975400_ljae287-B14","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","article-title":"Abrocitinib versus placebo or dupilumab for atopic dermatitis","volume":"384","author":"Bieber","year":"2021","journal-title":"N Engl J Med"},{"key":"2024111803540975400_ljae287-B15","doi-asserted-by":"crossref","DOI":"10.1001\/jamadermatol.2021.3023","article-title":"Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis","volume":"157","author":"Blauvelt","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2024111803540975400_ljae287-B16","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1111\/all.14324","article-title":"Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: results from the BioDay registry","volume":"75","author":"Spekhorst","year":"2020","journal-title":"Allergy"},{"key":"2024111803540975400_ljae287-B17","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/jamadermatol.2020.0796","article-title":"Systemic immunomodulatory treatments for patients with atopic dermatitis","volume":"156","author":"Drucker","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2024111803540975400_ljae287-B18","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1111\/jdv.17351","article-title":"Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis","volume":"35","author":"Silverberg","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024111803540975400_ljae287-B19","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jamadermatol.2022.0455","article-title":"Systemic immunomodulatory treatments for atopic dermatitis","volume":"158","author":"Drucker","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2024111803540975400_ljae287-B20","article-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2021"},{"key":"2024111803540975400_ljae287-B21","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1007\/s12325-022-02197-z","article-title":"Real-world effectiveness of newly initiated systemic therapy for atopic dermatitis in the United States: a claims database analysis","volume":"39","author":"Wu","year":"2022","journal-title":"Adv Ther"},{"key":"2024111803540975400_ljae287-B22","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1080\/09546634.2022.2038361","article-title":"Use of systemic therapies in adults with atopic dermatitis: 12-month results from the European prospective observational study in patients eligible for systemic therapy for atopic dermatitis (EUROSTAD)","volume":"33","author":"de Bruin-Weller","year":"2022","journal-title":"J\u00a0Dermatolog Treat"},{"key":"2024111803540975400_ljae287-B23","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","article-title":"Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies","volume":"90","author":"Davis","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2024111803540975400_ljae287-B24","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/jdv.18345","article-title":"European guideline (EuroGuiDerm) on atopic eczema: part I \u2013 systemic therapy","volume":"36","author":"Wollenberg","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024111803540975400_ljae287-B25","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1111\/jdv.18410","article-title":"Systemic treatment of children and adolescents with atopic dermatitis aged \u2265 2 years: a Delphi consensus project mapping expert opinion in Northern Europe","volume":"36","author":"de Graaf","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024111803540975400_ljae287-B26","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/bjd\/ljad281","article-title":"Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded clinical trial","volume":"189","author":"Flohr","year":"2023","journal-title":"Br J Dermatol"},{"key":"2024111803540975400_ljae287-B27","doi-asserted-by":"crossref","first-page":"100763","DOI":"10.1016\/j.waojou.2023.100763","article-title":"Effectiveness and safety of dupilumab in adults with moderate and severe atopic dermatitis in Colombia: real-life experience","volume":"16","author":"Londo\u00f1o","year":"2023","journal-title":"World Allergy Org J"},{"key":"2024111803540975400_ljae287-B28","author":"National Institute for Health and Care Excellence"},{"issue":"Suppl. 1","key":"2024111803540975400_ljae287-B29","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1089\/derm.2022.0069","article-title":"Efficacy of dupilumab in children 6\u2005months to 11\u2005years old with atopic dermatitis: a retrospective real-world study in China","volume":"35","author":"Yang","year":"2024","journal-title":"Dermatitis"},{"key":"2024111803540975400_ljae287-B30","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s13555-023-00894-3","article-title":"Dupilumab demonstrates rapid onset of action in improving signs, symptoms and quality of life in adults with atopic dermatitis","volume":"13","author":"Augustin","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2024111803540975400_ljae287-B31","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1111\/jdv.18849","article-title":"A nationwide 104 weeks real-world study of dupilumab in adults with atopic dermatitis: ineffectiveness in head-and-neck dermatitis","volume":"37","author":"Vittrup","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024111803540975400_ljae287-B32","first-page":"14","article-title":"Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin types","volume-title":"JAAD Int","author":"Bosma","year":"2023"},{"key":"2024111803540975400_ljae287-B33","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/1346-8138.16763","article-title":"Efficacy and safety of baricitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan","volume":"50","author":"Hagino","year":"2023","journal-title":"J Dermatol"},{"key":"2024111803540975400_ljae287-B34","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1684\/ejd.2022.4365","article-title":"Real-world effectiveness and safety of upadacitinib in Japanese patients with atopic dermatitis: a two-centre retrospective study","volume":"32","author":"Kosaka","year":"2022","journal-title":"Eur J Dermatol"},{"key":"2024111803540975400_ljae287-B35","first-page":"1175","article-title":"Efficacy and treatment satisfaction of different systemic therapies in children and adolescents with moderate-to-severe atopic dermatitis: a real-world study","volume":"12","author":"Kiefer","year":"2023","journal-title":"J\u00a0Clin Med"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljae287\/60094008\/ljae287.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/191\/6\/988\/60676346\/ljae287.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/191\/6\/988\/60676346\/ljae287.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,17]],"date-time":"2024-11-17T22:55:02Z","timestamp":1731884102000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/191\/6\/988\/7718940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":35,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,7,24]]},"published-print":{"date-parts":[[2024,11,18]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljae287","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,7,24]]}}}